Lv1
50 积分 2023-11-25 加入
Top advances of the year: Acute myeloid leukemia
3个月前
已完结
Revumenib: First Approval
4个月前
已完结
Quizartinib for Newly Diagnosed FLT3 -ITD–Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study
6个月前
已完结
Diagnosis and Treatment of Polycythemia Vera
7个月前
已完结
Polycythaemia vera
7个月前
已完结
Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022
7个月前
已完结
Multiple myeloma
7个月前
已完结
Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline FLT3 Inhibitor‐Based Therapy in FLT3‐Mutated AML
8个月前
已完结
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study
10个月前
已完结
皖公网安备34019202002308
